2013
Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice
Moreno JL, Holloway T, Rayannavar V, Sealfon SC, González-Maeso J. Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice. Neuroscience Letters 2013, 536: 69-73. PMID: 23333599, PMCID: PMC3578056, DOI: 10.1016/j.neulet.2012.12.053.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsAnimalsDrug AntagonismEarly Growth Response Protein 1Early Growth Response Protein 2HallucinogensLysergic Acid DiethylamideMaleMiceMice, KnockoutProto-Oncogene Proteins c-fosRadioligand AssayReceptor, Serotonin, 5-HT2AReceptors, Metabotropic GlutamateSomatosensory CortexStereotyped BehaviorXanthenesConceptsLysergic acid diethylamideChronic treatmentHallucinogenic drugsHallucinogenic effectsHead-twitch behaviorHallucinogenic 5MGlu2 receptorLast injectionSomatosensory cortexLY341495Serotonin 5Receptor bindingAcid diethylamideC-fosReceptor ligandsMiceDrugsTreatmentEgr-2Egr-1ReceptorsBehavioral responsesKnockoutHigh affinityMetabotropic
2012
Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function*
Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, Mocci G, Seto J, Callado LF, Neve RL, Milligan G, Sealfon SC, López-Giménez JF, Meana JJ, Benson DL, González-Maeso J. Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function*. Journal Of Biological Chemistry 2012, 287: 44301-44319. PMID: 23129762, PMCID: PMC3531745, DOI: 10.1074/jbc.m112.413161.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmino Acid MotifsAmino Acid SequenceAmino Acid SubstitutionAnimalsBehaviorCase-Control StudiesDimerizationFemaleHumansMaleMiceMice, 129 StrainMice, KnockoutMiddle AgedMolecular Sequence DataProtein BindingReceptor, Serotonin, 5-HT2AReceptors, Metabotropic GlutamateSchizophreniaSchizophrenic PsychologySequence AlignmentYoung AdultConceptsFrontal cortexMetabotropic glutamate 2 receptorGPCR heteromersBehavioral functionsMouse frontal cortexPsychosis-like effectsHallucinogenic 5Receptor neurotransmissionSchizophrenic subjectsReceptor heteromerizationReceptor complex formationSerotoninCortexHeteromeric expressionReceptorsReceptor heterocomplexDomain fourHeteromeric complexesCell signalingThree residuesHeteromersIntracellular endNeurotransmissionAgonistsMice
2011
Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors
Albizu L, Holloway T, González-Maeso J, Sealfon SC. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 2011, 61: 770-777. PMID: 21645528, PMCID: PMC3556730, DOI: 10.1016/j.neuropharm.2011.05.023.Peer-Reviewed Original ResearchConceptsMK-801-induced locomotor activityAlteration of serotoninDopamine D2 receptorsG protein-coupled receptor targetsFunctional crosstalkHEK293 cellsAntipsychotic effectsAntipsychotic drugsD2 receptorsSerotonin 5Dopamine systemLocomotor activityRadioligand bindingAgonist affinityReceptor targetsTherapeutic drugsReceptorsProduction assaysCo-immunoprecipitation studiesSerotoninReceptor heterocomplexDrugsActivationCellsAntagonistMetabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neuroscience Letters 2011, 493: 76-79. PMID: 21276828, PMCID: PMC3064746, DOI: 10.1016/j.neulet.2011.01.046.Peer-Reviewed Original ResearchConceptsLysergic acid diethylamideHallucinogen DOIBehavioral effectsHead-twitch behaviorC-fosEgr-2Hallucinogenic 5MGlu2 receptorReceptor agonistKnockout miceHigh-affinity binding sitesNeuropsychological responsesMiceAgonistsAcid diethylamideHallucinogenic drugsSignaling pathwaysCellular signaling pathwaysReceptorsFunctional interactionMembrane preparationsBehavioral responsesResponseWild typeSerotonin